HLA-C Antibody, HRP conjugated

說明書

中文名稱：

HLA-C兔多克隆抗體, HRP偶聯(lián)
貨號：

CSB-PA320739LB01HU
規(guī)格：

￥880
其他：

產(chǎn)品詳情
產(chǎn)品評價
相關(guān)產(chǎn)品
靶點(diǎn)詳情

產(chǎn)品詳情

產(chǎn)品名稱：

Rabbit anti-Homo sapiens (Human) HLA-C Polyclonal antibody
Uniprot No.：

P10321
基因名：

HLA-C
別名：

1C07_HUMAN antibody; Cw-7 alpha chain antibody; D6S204 antibody; HLA class I histocompatibility antigen antibody; HLA class I histocompatibility antigen; C alpha chain antibody; HLA class I histocompatibility antigen; Cw-1 alpha chain antibody; HLA JY3 antibody; HLA-C antibody; HLA-C histocompatibility type antibody; HLA-Cw antibody; HLA-JY3 antibody; HLAC antibody; HLC C antibody; HLC-C antibody; human leukocyte antigen-C alpha chain antibody; major histocompatibility antigen HLA-C antibody; major histocompatibility complex; class I; C antibody; MHC class I antigen antibody; MHC class I antigen Cw 1 antibody; MHC class I antigen Cw*7 antibody; MHC class I antigen heavy chain HLA-C antibody; PSORS1 antibody
宿主：

Rabbit
反應(yīng)種屬：

Human
免疫原：

Recombinant Human HLA class I histocompatibility antigen, Cw-7 alpha chain protein (62-306AA)
免疫原種屬：

Homo sapiens (Human)
標(biāo)記方式：

HRP
克隆類型：

Polyclonal
抗體亞型：

IgG
純化方式：

>95%, Protein G purified
濃度：

It differs from different batches. Please contact us to confirm it.
保存緩沖液：

Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, pH 7.4
產(chǎn)品提供形式：

Liquid
應(yīng)用范圍：

ELISA
Protocols：

ELISA Protocol
儲存條件：

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
貨期：

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
用途：

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

產(chǎn)品評價

靶點(diǎn)詳情

功能：

Antigen-presenting major histocompatibility complex class I (MHCI) molecule with an important role in reproduction and antiviral immunity. In complex with B2M/beta 2 microglobulin displays a restricted repertoire of self and viral peptides and acts as a dominant ligand for inhibitory and activating killer immunoglobulin receptors (KIRs) expressed on NK cells. In an allogeneic setting, such as during pregnancy, mediates interaction of extravillous trophoblasts with KIR on uterine NK cells and regulate trophoblast invasion necessary for placentation and overall fetal growth. During viral infection, may present viral peptides with low affinity for KIRs, impeding KIR-mediated inhibition through peptide antagonism and favoring lysis of infected cells. Presents a restricted repertoire of viral peptides on antigen-presenting cells for recognition by alpha-beta T cell receptor (TCR) on HLA-C-restricted CD8-positive T cells, guiding antigen-specific T cell immune response to eliminate infected cells, particularly in chronic viral infection settings such as HIV-1 or CMV infection. Both the peptide and the MHC molecule are recognized by TCR, the peptide is responsible for the fine specificity of antigen recognition and MHC residues account for the MHC restriction of T cells. Typically presents intracellular peptide antigens of 9 amino acids that arise from cytosolic proteolysis via proteasome. Can bind different peptides containing allele-specific binding motifs, which are mainly defined by anchor residues at position 2 and 9. Preferentially displays peptides having a restricted repertoire of hydrophobic or aromatic amino acids (Phe, Ile, Leu, Met, Val and Tyr) at the C-terminal anchor.; ALLELE C*01:02: The peptide-bound form interacts with KIR2DL2 and KIR2DL3 inhibitory receptors on NK cells. The low affinity peptides compete with the high affinity peptides impeding KIR-mediated inhibition and favoring lysis of infected cells. Presents to CD8-positive T cells a CMV epitope derived from UL83/pp65 (RCPEMISVL), an immediate-early antigen necessary for initiating viral replication.; ALLELE C*04:01: Presents a conserved HIV-1 epitope derived from env (SFNCGGEFF) to memory CD8-positive T cells, eliciting very strong IFNG responses. Presents CMV epitope derived from UL83/pp65 (QYDPVAALF) to CD8-positive T cells, triggering T cell cytotoxic response.; ALLELE C*05:01: Presents HIV-1 epitope derived from rev (SAEPVPLQL) to CD8-positive T cells, triggering T cell cytotoxic response.; ALLELE C*06:02: In trophoblasts, interacts with KIR2DS2 on uterine NK cells and triggers NK cell activation, including secretion of cytokines such as GMCSF that enhances trophoblast migration.; ALLELE C*07:02: Plays an important role in the control of chronic CMV infection. Presents immunodominant CMV epitopes derived from IE1 (LSEFCRVL and CRVLCCYVL) and UL28 (FRCPRRFCF), both antigens synthesized during immediate-early period of viral replication. Elicits a strong anti-viral CD8-positive T cell immune response that increases markedly with age.; ALLELE C*08:01: Presents viral epitopes derived from CMV UL83 (VVCAHELVC) and IAV M1 (GILGFVFTL), triggering CD8-positive T cell cytotoxic response.; ALLELE C*12:02: Presents CMV epitope derived from UL83 (VAFTSHEHF) to CD8-positive T cells.; ALLELE C*15:02: Presents CMV epitope derived from UL83 CC (VVCAHELVC) to CD8-positive T cells, triggering T cell cytotoxic response.
基因功能參考文獻(xiàn)：
1. This study suggests that polytransfused patients with SCA possessing the HLA-DQB1*03 and HLA-C*06 allele variants are more susceptible to alloimmunisation. In addition, HLA-DRB1*04 and HLA-DRB1*11 alleles were seen to be associated with the production of anti-Fy(a) and anti-K antibodies, respectively. PMID: 28881103
2. Binding stability to beta2-microglobulin may confer to HLA-C the ability to preferentially act either as a conventional immune-competent molecule or as an accessory molecule involved in HIV-1 infectivity via viral envelope glycoprotein binding. PMID: 28051183
3. the results show that HLA-C incompatibility between couples is significantly associated with unexplained recurrent miscarriage PMID: 29205643
4. this study shows that HLA-C genetic variance is associated with HIV-1 viral load in seroconverters from Zambia and Rwanda PMID: 29289742
5. this study shows that HLA-C1 ligands are associated with increased susceptibility to systemic lupus erythematosus PMID: 29395276
6. this study demonstrates associations of ERAP1 coding variants and domain specific interaction with HLA-C *06 in the early onset psoriasis patients of India PMID: 28867178
7. Confirmation of the HLA-C*16:97 allele in multiple individuals in Italy, Croatia, Greece, and Turkey has been reported. PMID: 28155256
8. The results from this large cohort of European patients treated with ustekinumab in daily clinical practice confirm the role of HLA-C*06 as a potential predictor of response to ustekinumab. PMID: 28207934
9. In silico docking study have confirmed the high binding affinities of multiple 9-mer peptides derived from LL-37 to the HLA-C*06:02 molecule proposed a mechanism of the interaction between this LL-37-HLA-C*06:02 complex and T cells via TCRs. PMID: 27189829
10. Individuals carrying HLA-C rs9264942 TT genotype showed a significant increased level of HIV-1 viral load pre-treatment, in comparison with individuals carrying the CC genotype (p-value = 0.0092). PMID: 28494720
11. Human Leukocyte Antigen C*12:02:02 and Killer Immunoglobulin-Like Receptor 2DL5 are Distinctly Associated with Ankylosing Spondylitis in the Taiwanese PMID: 28812990
12. these study reports an association of the ERAP1 SNP rs30187 with the HLA-C*07 allele in inflammatory bowel disease in the Spanish population PMID: 28651467
13. The likely HLA class I C*05:142-bearing haplotype is A*02:01~C*05:142~B*44:02. This new allele has a maximum frequency of 0.00001, in 34,743 sequenced-based typed subjects, contrasting with that of C*05:01 (allele frequency 0.10441), in our local, largely UK European, blood donors. PMID: 28639429
14. In this study, we describe and confirm the distinct expression of HLA-F, HLA-G, HLA-E, and HLA-C in placental tissue PMID: 28185362
15. childhood acute lymphoblastic leukaemic patients but not healthy controls exhibited B cell populations with very low HLA-C and -E expression levels that could be consistently allocated to the CD19+CD45- leukaemic subset PMID: 26527563
16. propose that HIV-1 infectivity might depend both on the amounts of HLA-C molecules and on their stability as trimeric complex. According to this model, individuals with low-expression HLA-C alleles and unstable binding to beta2m/peptide might have worse control of HIV-1 infection and an intrinsically higher capacity to support viral replication PMID: 29070683
17. This study suggests a possible role of killer cell immunoglobulin-like receptors and their ligands in the development of liver damage. The absence of human leucocyte antigen C1 and C2 ligands heterozygosity could lead to less inhibition of natural killer cells and a quicker progression to a high level of fibrosis in patients infected with hepatitis C virus, especially following liver transplantation. PMID: 26717049
18. KIR2DL2/HLA-C( *)12:02 and KIR2DL2/HLA-C( *)14:03 compound genotypes have protective effects on control of HIV-1. PMID: 27880898
19. Data establish the C2 allele as a novel genetic risk factor associated with congenital heart block. This observation supports a model in which fetuses with C2 ligand expression and maternal anti-SSA/Ro positivity may have impaired NK cell surveillance, resulting in unchecked cardiac inflammation and scarring. PMID: 29045069
20. results provide the structural basis for understanding peptide repertoire selection in HLA-C*06:02. PMID: 28855257
21. Single-nucleotide polymorphisms FOXF1 rs9936833 and MHC rs9257809 remained significantly associated with presence of gastroesophageal acid reflux. The association for risk allele C in FOXF1 rs9936833 and risk allele A in MHC rs9257809 with the presence of acid reflux suggests a potential pathophysiologic mechanism for the role of genetic influences in Barret Esophagus development. PMID: 26822871
22. The minor alleles of rs2395029, rs9264942, and rs3689068 in the HCP5 and HLA-C, and ZNRD1 genes associate with lower viral loads (VL) among antiretroviral-naive individuals and with shorter time to first VL less 51 copies/ml during anti-HIV therapy. PMID: 27083073
23. HLA-C*04:01 predisposes to nevirapine-induced Stevens-Johnson syndrome/toxic epidermal necrolysis in , but not to other hypersensitivity phenotypes in a sub-Saharan African HIV-infected population PMID: 28062682
24. Genotyping analysis revealed that HLA-C2, which provides a ligand for killer-cell immunoglobulin-like receptors (KIR) expressed by NK cells, was strongly associated with psoriasis susceptibility. However, no link between the KIR genes themselves and disease was found PMID: 26477484
25. the signal overall signal that NK cells receive from paternal HLA-C on trophoblasts depends on the ratio of activating and inhibitory KIR genes expressed by them PMID: 27751789
26. data strengthen our understanding of HLA-C transcriptional regulation and provide a basis for understanding the potential consequences of manipulating HLA-C levels therapeutically PMID: 27817866
27. KIR2DS2/HLA-C1 may correlate with Hashimoto Thyroiditis pathogenesis. PMID: 27042744
28. The data suggested the association of IL12B with the psoriasis, however no evidence was observed for the epistatic effect of IL12B with HLA-Cw6 among the psoriasis patients in India. PMID: 27829679
29. this study first demonstrates hypermethylation of HLA-C gene in psoriatic epidermis, suggesting that HLA-C hypermethylation may be an epigenetic marker in psoriasis. PMID: 27132688
30. Homozygous HLA-Cw*0602 carriage in plaque psoriasis may predict a favorable outcome after tonsillectomy. The homozygotes more often had psoriasis onset associated with a throat infection and an increased frequency of streptococcal throat infections per lifetime. PMID: 27520394
31. the combined effect of HLA-Cw6 allele and risk associated genotype near LCE3A gene has a role in psoriasis in the Indian population PMID: 27048876
32. The absence of KIR-2DS1 in the mother and the presence of HLA-C2 ligand in the child were negatively associated with type 1 diabetes in the child. Our results indicate that maternal KIR genes and their interaction with foetal HLA-C2 may contribute to the risk of type 1 diabetes among Han Chinese children PMID: 26991115
33. this study shows that in HIV infection, spontaneous controllers express higher levels of HLA-C, along with NK cell activation PMID: 27521484
34. these results suggest that the HLA-C*06 allele is positively associated with susceptibility to psoriasis, female gender and early onset of psoriasis in South Indian Tamils. PMID: 26796545
35. gene polymorphism is associated with Crohn's disease in Spanish patients PMID: 26542067
36. Recurrent Pregnancy Loss in Women with Killer Cell Immunoglobulin-Like Receptor KIR2DS1 is Associated with an Increased HLA-C2 Allelic Frequency PMID: 26589762
37. genetic polymorphism is associated with the course of Hepatitis C virus infection and the response to therapy PMID: 26206121
38. HLA-C genetic polymorphism is associated with psoriasis. PMID: 26470763
39. HLA-C2 and -C1, showed highly significant associations with CRC development. PMID: 26383988
40. Therefore, the results obtained in this study demonstrate the involvement of HLA class I genes in the susceptibility or resistance to American cutaneous leishmaniasis (ACL), with significant association between HLA-C*04 and ACL susceptibility. PMID: 26600554
41. HLA-C expressed on HIV-infected cells restricts attack by KIR2DL(+) CD56(dim) natural killer (NK) cells PMID: 26828202
42. Absence of HLA-C2 for donor KIR2DL1 was associated with higher grade II to IV (HR, 1.4; P = .002) and III to IV acute GVHD (HR, 1.5; P = .01) compared with HLA-C2(+) patients. PMID: 25960307
43. The authors have identified a deleterious effect of the KIR2DL3-HLA-C1 receptor-ligand combination on HIV clinical outcomes in a Thai cohort. PMID: 26372271
44. HLA-C -35 C/C allele exerts a favorable effect on the immunological (higher baseline and nadir CD4+ T cell count) and virologic (lower pretreatment HIV viral load) variables. PMID: 26068923
45. Preformed anti-HLA-Cw and anti-HLA-DP donor specific antibodies have deleterious impact in kidney transplantation. PMID: 26262501
46. Data suggest regulatory interactions between major histocompatibility antigen HLA-C and killer cell Ig-like receptor (KIR) might promote Graft-versus-Leukemia effects following transplantation. PMID: 26416275
47. combination of maternal KIR AA with fetal HLA-C2 associated with increased incidence of preeclampsia in Chinese Han population PMID: 24911933
48. ). In conclusion, we found an interaction between the HLA-Cw6 and LCE genotypes on disease improvement among psoriatic patients treated with anti-TNFs. PMID: 25794162
49. Possible protective role of human leukocyte antigen Cw7 indicates polyoma BK virus-positive people can be accepted safely for kidney donation. PMID: 25894195
50. this is the first molecular study of HLA typing in Egyptian patients with vitiligo PMID: 25844609
顯示更多

收起更多
亞細(xì)胞定位：

Cell membrane; Single-pass type I membrane protein. Endoplasmic reticulum membrane; Single-pass membrane protein.
蛋白家族：

MHC class I family
組織特異性：

Ubiquitous. Highly expressed in fetal extravillous trophoblasts in the decidua basalis (at protein level).
數(shù)據(jù)庫鏈接：

HGNC: 4933

OMIM: 142840

KEGG: hsa:3107

STRING: 9606.ENSP00000365402

UniGene: Hs.656020

Most popular with customers

YWHAG Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
YWHAB Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF, FC

Species Reactivity: Human, Mouse, Rat
Phospho-YAP1 (S127) Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
XRCC5 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF

Species Reactivity: Human
XPNPEP1 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human
XDH Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WFDC2 Recombinant Monoclonal Antibody

Applications: ELISA, WB, FC

Species Reactivity: Human
WDR5 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human